Regeneron Pharmaceuticals (NASDAQ:REGN) Earns “Sector Perform” Rating from Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “sector perform” rating reaffirmed by equities research analysts at Royal Bank Of Canada in a report released on Tuesday, Benzinga reports. They currently have a $737.00 target price on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 0.92% from the company’s previous close.

A number of other equities research analysts have also commented on REGN. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. HSBC raised their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Leerink Partners raised their target price on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. Finally, Citigroup raised their target price on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $809.50.

Regeneron Pharmaceuticals Trading Down 0.7%

Shares of Regeneron Pharmaceuticals stock opened at $730.30 on Tuesday. The stock has a market capitalization of $75.19 billion, a P/E ratio of 18.06, a price-to-earnings-growth ratio of 1.41 and a beta of 0.16. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The company has a 50-day simple moving average of $788.30 and a 200 day simple moving average of $720.68. Regeneron Pharmaceuticals has a 12-month low of $541.00 and a 12-month high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same quarter last year, the company posted $12.81 EPS. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. Research analysts expect that Regeneron Pharmaceuticals will post 45.34 earnings per share for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Huda Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 31.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the sale, the director owned 603 shares in the company, valued at $512,550. This represents a 39.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,946 shares of company stock worth $3,302,458 in the last ninety days. Company insiders own 6.97% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds have recently modified their holdings of REGN. CX Institutional raised its position in shares of Regeneron Pharmaceuticals by 30.1% in the 3rd quarter. CX Institutional now owns 501 shares of the biopharmaceutical company’s stock valued at $380,000 after acquiring an additional 116 shares during the period. Versant Capital Management Inc raised its holdings in Regeneron Pharmaceuticals by 55.2% during the 3rd quarter. Versant Capital Management Inc now owns 534 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 190 shares during the period. Envestnet Asset Management Inc. raised its holdings in Regeneron Pharmaceuticals by 0.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 109,838 shares of the biopharmaceutical company’s stock worth $68,488,000 after buying an additional 686 shares during the period. Andra AP fonden raised its holdings in Regeneron Pharmaceuticals by 583.2% during the 2nd quarter. Andra AP fonden now owns 28,912 shares of the biopharmaceutical company’s stock worth $18,028,000 after buying an additional 24,680 shares during the period. Finally, State Street Corp raised its holdings in Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after buying an additional 170,210 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.